RT Journal Article
SR Electronic
T1 Kinetics of viral load, immunological mediators and characterization of a SARS-CoV-2 isolate in mild COVID-19 patients during acute phase of infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.05.20226621
DO 10.1101/2020.11.05.20226621
A1 Anantharaj, Anbalagan
A1 Gujjar, Sunil
A1 Kumar, Saurabh
A1 Verma, Nikhil
A1 Wangchuk, Jigme
A1 Khan, Naseem Ahmed
A1 Panwar, Aleksha
A1 Kanakan, Akshay
A1 A, Vivekanand
A1 Vasudevan, Janani Srinivasa
A1 Das, Asim
A1 Pandey, Anil Kumar
A1 Pandey, Rajesh
A1 Medigeshi, Guruprasad R.
YR 2020
UL http://medrxiv.org/content/early/2020/11/08/2020.11.05.20226621.abstract
AB Over 95% of the COVID-19 cases are mild-to-asymptomatic who contribute to disease transmission whereas most of the severe manifestations of the disease are observed in elderly and in patients with comorbidities and dysregulation of immune response has been implicated in severe clinical outcomes. However, it is unclear whether asymptomatic or mild infections are due to low viral load or lack of inflammation. We have measured the kinetics of SARS-CoV-2 viral load in the respiratory samples and serum markers of inflammation in hospitalized COVID-19 patients with mild symptoms. We observed a bi-phasic pattern of virus load which was eventually cleared in most patients at the time of discharge. Viral load in saliva samples from a subset of patients showed good correlation with nasopharyngeal samples. Serum interferon levels were downregulated during early stages of infection but peaked at later stages correlating with elevated levels of T-cell cytokines and other inflammatory mediators such as IL-6 and TNF- α which showed a bi-phasic pattern. The clinical recovery of patients correlated with decrease in viral load and increase in interferons and other cytokines which indicates an effective innate and adaptive immune function in mild infections. We further characterized one of the SARS-CoV-2 isolate by plaque purification and show that infection of lung epithelial cells (Calu-3) with this isolate led to cytopathic effect disrupting epithelial barrier function and tight junctions. Finally we showed that zinc was capable of inhibiting SARS-CoV-2 infection in this model suggesting a beneficial effect of zinc supplementation in COVID-19 infection.IMPORTANCE A majority of COVID-19 patients are asymptomatic or exhibit mild symptoms despite high viral loads suggesting a key role for the acute phase innate immune response in limiting the damage and clearing the virus. Therefore, it is important to understand the early phase response to SARS-CoV-2 infection in such patients to devise strategies for clinical management of the disease. Our study shows the kinetics of immune mediators in the serum samples collected from hospitalized COVID-19 patients with mild symptoms. We further characterize a virus isolate from one of these patients and demonstrate its effect on epithelial barrier functions and show that zinc was capable of inhibiting SARS-CoV-2 infection under these conditions. Our results suggest a key role for the innate immune responses in the early phase of infection in mitigating clinical symptoms, clearing the virus and recovery from illness and suggest an antiviral role for zinc in COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding to GRM by the Biotechnology Industry Research Assistance Council (BIRAC) (BT/NBM0099/02/18). GRM also received funding from the DBT-Wellcome trust India Alliance intermediate fellowship (IA/S/14/1/501291). RP acknowledges funding support from CSIR (MLP-2005), and FondationBotnar (CLP-0031). The funders had no role in study design, data collection and interpretation or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional ethics committees for human research at both the institutions (No. 134/A/11/16/Academics/MC/2016/134 and THS 1.8.1/ (93)). Informed consent was obtained from all the participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data are presented within the manuscript and as supplemental information and is freely available.